Dallas, TX -- (SBWIRE) -- 05/29/2010 -- ReportsandReports announce it will carry Pneumonia - Drug Pipeline Analysis and Market Forecasts to 2016 Market Research Report in its Store.
Pneumonia - Drug Pipeline Analysis and Market Forecasts to 2016
Summary
GlobalData’s pharmaceutical and healthcare report offering, “Pneumonia - Drug Pipeline Analysis and Market Forecasts to 2016”. is an essential source of information and analysis on the global pneumonia market. The report identifies the key trends shaping and driving the global pneumonia market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to cause significant shifts in the market positioning of the existing market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global pneumonia sector.
Pneumonia - Drug Pipeline report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.
GlobalData’s analysis suggests that the global pneumonia market was worth $1.4 billion in 2009. It is forecast to decline at a Compound Annual Growth Rate (CAGR) of 4.3% for the next seven years to reach $1 billion by 2016. The projected decline rate is primarily attributable to the patent expiries of Levaquin, Avelox and Zyvox by the end of the forecast period. Increases in the treatment seeking population, the diagnosis population and the ever-increasing development of bacterial resistance to marketed antibiotics are expected to sustain the pneumonia market.
Scope
The scope of the report includes:
* Annualized global pneumonia market revenues data from 2000 to 2009, forecast for seven years to 2016.
* Key geographies covered in this report include the Unites States (US), the United Kingdom (UK), Italy, Spain, Germany, France and Japan.
* Pipeline analysis data providing a split across different phases, mechanism of action being developed and emerging trends. The key classes of mechanism of action are cell wall synthesis inhibitors, protein synthesis inhibitors and topoisomerase II and topoisomerase IV inhibitors.
* Analysis of the current and future market competition in the global pneumonia market. The key market players covered are AstraZeneca, Pfizer, Bayer, GSK and J&J Pharmaceuticals.
* Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
* Key topics covered include a strategic competitor assessment, market characterization, unmet needs and implications for the future pneumonia market.
Reasons to buy
The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:
* Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.
* Develop business strategies by understanding the trends shaping and driving the global pneumonia market.
* Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global pneumonia market in future.
* Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
* Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
* Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
* What’s the next big thing in the global pneumonia market landscape? – Identify, understand and capitalize.
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Pnemonia Therapeutics Market: Market Characterization
2.1 Overview
2.2 Pneumonia Therapeutics Market Size
2.3 Pneumonia Therapeutics Market Forecast and CAGR
2.4 Drivers and Barriers for the Pneumonia Therapeutics Market
2.4.1 Drivers for the Pneumonia Therapeutics Market
2.4.2 Barriers for the Pneumonia Therapeutics Market
2.5 Opportunity and Unmet Need
2.6 Key Takeaway
3 Pneumonia Therapeutics Market: Competitive Assessment
3.1 Overview
3.2 Strategic Competitor Assessment
3.3 Product Portfolio for Major Marketed Products in the Pneumonia Therapeutics Market
3.3.1 Zyvox (linezolid)
3.3.2 Zosyn (piperacillin and tazobactam)
3.3.3 Levaquin (levofloxacin)
3.3.4 Avelox (moxifloxacin)
3.3.5 Omnicef (cefdinir)
3.3.6 Tygacil (tigecycline)
3.3.7 Doribax (doripenem)
3.4 Key Takeaway
4 Pneumonia Therapeutics Market: Pipeline Assessment
4.1 Overview
4.2 Strategic Pipeline Assessment
4.2.1 Technology Trends Analytical Framework
4.3 Pneumonia Therapeutics - Promising Drugs under Clinical Development
4.4 Molecule Profiles for Promising Drugs under Clinical Development
4.4.1 Ceftaroline
4.4.2 Ceftobiprole medocaril
4.4.3 Restanza (cethromycin)
4.4.4 Vibativ (telavancin)
4.5 Pneumonia Therapeutics Market - Pipeline Assessment by Mechanism of Action
4.6 Pneumonia Therapeutics Market - Pipeline Assessment by Phase of Clinical Development
4.6.1 Pneumonia Therapeutics - Phase III Clinical Pipeline
4.6.2 Pneumonia Therapeutics - Phase II Clinical Pipeline
4.6.3 Pneumonia Therapeutics - Phase I Clinical Pipeline
4.6.4 Pneumonia Therapeutics - Preclinical Pipeline
4.6.5 Pneumonia Therapeutics - Discovery Pipeline
4.7 Discontinued/Suspended Drugs for Pneumonia
4.8 Key Takeaway
5 Pneumonia Therapeutics Market: Implications for Future Market Competition
6 Pneumonia Therapeutics Market: Future Players in the Pneumonia Therapeutics Market
6.1 Forest Laboratories, Inc.
6.1.1 Company Overview
6.1.2 Ceftaroline
6.2 Basilea Pharmaceutica
6.2.1 Company Overview
6.2.2 Ceftobiprole medocaril
6.3 Advanced Life Sciences
6.3.1 Company Overview
6.3.2 Restanza (cethromycin)
6.4 Theravance, Inc.
6.4.1 Company Overview
6.4.2 Vibativ (telavancin)
7 Pneumonia Therapeutics Market: Appendix
7.1 Definitions
7.2 Acronyms
7.3 Research Methodology
7.4 Coverage
7.5 Secondary Research
7.6 Primary Research
7.7 Models
7.8 Forecasts
7.9 Expert Panels
7.10 Sources
7.11 GlobalData Consulting
7.12 Contact Us
7.13 Disclaimer
1.1 List of Tables
Table 1: Empirical Antimicrobial Therapy for Pneumonia, 2010
Table 2: Pneumonia Therapeutics Market, Global, Revenues ($m), 2001-2009
Table 3: Pneumonia Therapeutics Market, Global, Revenue Forecasts ($m), 2009-2016
Table 4: Cure Rates of Zyvox in Nosocomial Pneumonia, 2010
Table 5: Cure Rates of Zyvox in Community-Acquired Pneumonia due to MDRSP, 2010
Table 6: Pneumonia Therapeutics Market, Global, Most Promising Molecules under Clinical Development, May 2010
Table 7: Pneumonia Therapeutics Market, Global, Phase III Clinical Pipeline, 2010
Table 8: Pneumonia Therapeutics Market, Global, Phase II Clinical Pipeline, 2010
Table 9: Pneumonia Therapeutics Market, Global, Phase I Clinical Pipeline, 2010
Table 10: Pneumonia Therapeutics Market, Global, Preclinical Pipeline, 2010
Table 11: Pneumonia Therapeutics Market, Global, Discovery Pipeline, 2010
Table 12: Pneumonia Therapeutics Market, Global, List of Discontinued Drugs, 2010
1.2 List of Figures
Figure 1: Pneumonia Therapeutics Market, Global, Revenues ($m), 2001-2009
Figure 2: Pneumonia Therapeutics Market, Global, Revenue Forecasts ($m), 2009-2016
Figure 3: Pneumonia Therapeutics Market, Global, Opportunity and Unmet Need, 2010
Figure 4: Pneumonia Therapeutics Market, Global, Strategic Competitor Assessment of the Major Marketed Products, 2010
Figure 5: Pneumonia Therapeutics Pipeline, Global, Technology Trends Analytic Framework, 2010
Figure 6: Pneumonia Therapeutics Market, Global, Technology Trends Analytic Framework, Description—2010
Figure 7: Pneumonia Therapeutics Market, Global, Clinical Pipeline by Mechanism of Action, 2010
Figure 8: Pneumonia Therapeutics Market, Global, Clinical Pipeline, 2010
Figure 9: Pneumonia Therapeutics Market, Global, Implications for Future Market Competition, 2010
Figure 10: Pneumonia Therapeutics Market, Global, Clinical Pipeline by Company, 2010
Figure 11: GlobalData Methodology, 2010
Browse complete report at: http://www.reportsandreports.com/market-reports/pneumonia-drug-pipeline-analysis-and-market-forecasts-to-2016/
Browse all Healthcare Market Research Reports at:
http://www.reportsandreports.com/market-research/healthcare/
Browse all GlobalData Market Research Reports at:
http://www.reportsandreports.com/Publishers/globaldata/
Related Reports:
http://www.reportsandreports.com/market-reports/anemia-drug-pipeline-analysis-and-market-forecasts-to-2016/
http://www.reportsandreports.com/market-reports/acne-drug-pipeline-analysis-and-market-forecasts-to-2016/
http://www.reportsandreports.com/market-reports/hemophilia-drug-pipeline-analysis-and-market-forecasts-to-2016/
About Reports and Reports
Reports and Reports comprises an online library of 10,000 reports, in-depth market research studies of over 5000 micro markets, and 25 industry specific websites. Our client list boasts almost all well-known publishers of such reports across the globe. We as a third-party reseller of market research reports employ a number of marketing tools, such as press releases, email-marketing and effective search-engine optimization techniques to drive revenues for our clients. We also provide 24/7 online and offline support service to our customers.
Contact:
Ms. Sunita
7557 Rambler road,
Suite 727, Dallas, TX 75231
Tel: +1-888-989-8004
Website: http://www.reportsandreports.com/
Blog: http://reportsnreports.wordpress.com/